Candel Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
CADL$9.35-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| COMMON STOCK · TREASURY STOCK | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHARES · AMOUNT · SHARES · AMOUNT · ADDITIONALPAID-IN CAPITAL · ACCUMULATEDDEFICIT · STOCKHOLDERS’EQUITY | |||||||||||
| Balance as of December 31, 2021 | 28,689,842 | $286 | — | $— | $144,146 | $(80,295) | $64,137 | ||||
| Options exercised | 352,576 | 4 | — | — | 508 | — | 512 | ||||
| Treasury stock acquired | (122,608) | (448) | — | (448) | |||||||
| Stock-based compensation | — | — | — | — | 3,145 | — | 3,145 | ||||
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | (838) | — | (838) | ||||
| Net loss | — | — | — | — | — | (18,794) | (18,794) | ||||
| Balance as of December 31, 2022 | 29,042,418 | $290 | (122,608) | $(448) | $146,961 | $(99,089) | $47,714 | ||||
| Stock-based compensation | — | — | — | — | 3,137 | — | 3,137 | ||||
| Restricted stock unit vesting, net of shares withheld for taxes | 171,209 | — | — | — | (121) | — | (121) | ||||
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | (46) | — | (46) | ||||
| Net loss | — | — | — | — | — | (37,939) | (37,939) | ||||
| Balance as of December 31, 2023 | 29,213,627 | $290 | (122,608) | $(448) | $149,931 | $(137,028) | $12,745 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.